Edition:
United States

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

13.25USD
26 Sep 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.25
Open
$13.40
Day's High
$13.40
Day's Low
$13.10
Volume
4,260
Avg. Vol
34,645
52-wk High
$15.90
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $331.37
Shares Outstanding(Mil.): 25.01
Dividend: --
Yield (%): --

Financials

  XENE.OQ Industry Sector
P/E (TTM): -- 113.18 32.94
EPS (TTM): -1.60 -- --
ROI: -48.52 1.56 12.84
ROE: -66.54 0.73 14.95

BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference

* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE

May 15 2018

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

May 08 2018

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

May 01 2018

Earnings vs. Estimates